October 26, 2018
There has been significant debate regarding the safety of achieving very low LDL-C levels, including a potential negative impact on cognitive function. The current ACC/AHA guidelines (circa 2013) suggest decreasing the statin dose in patients with two consecutive LDL-C levels below 40 mg/dL based on expert opinion. The lack of evidence has been a major challenge for clinicians and it is unclear whether medication doses should be reduced in high-risk patients who may benefit from very low LDL-C levels. A recently published meta-analysis sought to address this clinical dilemma.
Podcast Case: Very Low LDL Case
Guest Authors: Apryl Anderson, PharmD and Dave Dixon, PharmD, BCPS, BCACP, CLS, CDE
Music by Good Talk
December 15, 2017
We interview Eric MacLaughlin, Joseph Saseen, and Kristin Rieser about the ACC/AHA Guidelines for the Prevention, Detection, Evaluation, and Treatment of High Blood Pressure in Adults released in November 2017. Dr. MacLaughin, a member of the Guideline Writing Committee, gives a insiders view of the guidelines development process and explains the rationale for lower blood pressure goals. Drs. Saseen and Rieser talk about some of the practical considerations that we all must consider as we move forward to making these recommendations a reality.
Guests: Kristin Rieser, Pharm.D., Joseph Saseen, Pharm.D, and Eric MacLaughlin, Pharm.D.
Music by Good Talk
February 10, 2016
The debate over the intensity of blood pressure
(BP) lowering for patients with hypertension has been going on for decades. Additional fuel to the fire was recently added
with the early halt and publication of the Systolic Blood Pressure Intervention
Trial (SPRINT). So “how low should
you go” for patients with high BP? Do lower BP goals reduce CV outcomes and
death, particularly in patients at high risk?
Do they cause greater adverse effects? Or perhaps even worsen CV outcomes?
These questions were examined in SPRINT.